BR112015018270A2 - composições que compreendem 15-ohepa e métodos de uso das mesmas - Google Patents

composições que compreendem 15-ohepa e métodos de uso das mesmas

Info

Publication number
BR112015018270A2
BR112015018270A2 BR112015018270A BR112015018270A BR112015018270A2 BR 112015018270 A2 BR112015018270 A2 BR 112015018270A2 BR 112015018270 A BR112015018270 A BR 112015018270A BR 112015018270 A BR112015018270 A BR 112015018270A BR 112015018270 A2 BR112015018270 A2 BR 112015018270A2
Authority
BR
Brazil
Prior art keywords
ohepa
compositions
methods
fatty liver
alcoholic
Prior art date
Application number
BR112015018270A
Other languages
English (en)
Inventor
Climax John
Rowe Jonathan
Duffy Kevin
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of BR112015018270A2 publication Critical patent/BR112015018270A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo “composições que compreendem 15-ohepa e métodos de uso das mesmas” a presente invenção se refere a composições, formulações e métodos de tratamento de distúrbios hepáticos gordurosos, tais como doença hepática gorduro-sa não-alcoólica (nafld) e esteatoepatite não-alcoólica (nash) e suas sequelas através da administração de 15-ohepa.
BR112015018270A 2013-01-30 2014-01-24 composições que compreendem 15-ohepa e métodos de uso das mesmas BR112015018270A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Publications (1)

Publication Number Publication Date
BR112015018270A2 true BR112015018270A2 (pt) 2017-07-18

Family

ID=47891001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015018270A BR112015018270A2 (pt) 2013-01-30 2014-01-24 composições que compreendem 15-ohepa e métodos de uso das mesmas

Country Status (28)

Country Link
US (5) US20150224076A1 (pt)
EP (2) EP2762143B1 (pt)
JP (2) JP6363104B2 (pt)
KR (5) KR102274963B1 (pt)
CN (2) CN111214464A (pt)
AU (2) AU2014211628B2 (pt)
BR (1) BR112015018270A2 (pt)
CA (1) CA2897343C (pt)
CY (1) CY1117209T1 (pt)
DK (1) DK2762143T3 (pt)
ES (2) ES2759448T3 (pt)
GB (1) GB201301626D0 (pt)
HK (1) HK1200351A1 (pt)
HR (1) HRP20160203T1 (pt)
HU (1) HUE026901T2 (pt)
IL (3) IL239893A (pt)
MX (2) MX364646B (pt)
NZ (1) NZ709803A (pt)
PH (1) PH12015501582B1 (pt)
PL (1) PL2762143T3 (pt)
PT (1) PT2762143E (pt)
RS (1) RS54584B1 (pt)
RU (2) RU2671208C2 (pt)
SG (2) SG10201806854XA (pt)
SI (1) SI2762143T1 (pt)
SM (1) SMT201600069B (pt)
WO (1) WO2014118097A1 (pt)
ZA (2) ZA201505018B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3878835A1 (en) 2013-11-15 2021-09-15 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
JP2017505809A (ja) * 2014-01-10 2017-02-23 ディグニティ サイエンシス リミテッド １５−ｈｅｐｅを含む薬学的組成物ならびにこれを用いた喘息及び肺障害の治療方法
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
WO2016113635A1 (en) * 2015-01-16 2016-07-21 Dignity Sciences Limited Compositions comprising 15-hepe and methods of using the same
JP6784696B2 (ja) 2015-04-28 2020-11-11 プロノヴァ バイオファーマ ノルゲ エーエス 硫黄を含有する構造的に強化された脂肪酸の非アルコール性脂肪性肝炎の予防及び／又は治療のための使用
MA47141A (fr) * 2015-05-13 2019-11-06 Ds Biopharma Ltd Compositions comprenant du15-oxo-epa ou du 15-oxo-dgla et leurs procédés de préparation et d'utilisation
JP2018520197A (ja) 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
US9855238B2 (en) * 2015-12-18 2018-01-02 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
SG11202005007VA (en) 2017-12-06 2020-06-29 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
ES2112567T3 (es) 1993-10-01 1998-04-01 Scherer Corp R P Procedimientos y composiciones para administrar fragancias.
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
ATE344226T1 (de) * 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
BR0209749A (pt) 2001-05-30 2004-07-27 Laxdale Ltd Coenzima q e epa ou outro ácido graxo essencial
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
MX2007000208A (es) 2004-07-01 2007-08-07 Schepens Eye Res Inst Composiciones y metodos para tratar trastornos y condiciones del ojo.
US20070265340A1 (en) * 2006-01-05 2007-11-15 Shalwitz Robert A Treatment of fatty liver
US20100233724A1 (en) 2006-08-08 2010-09-16 Watkins Steven M Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
US20100120914A1 (en) * 2007-03-30 2010-05-13 Kowa Company, Ltd. Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JPWO2009154230A1 (ja) * 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP2415748A4 (en) * 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
WO2012023254A1 (ja) * 2010-08-19 2012-02-23 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
AU2012324853A1 (en) 2011-10-19 2014-05-01 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
BR112014013098A2 (pt) 2011-11-29 2017-06-13 Dignity Sciences Ltd composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos
US20150004224A1 (en) 2012-01-06 2015-01-01 Omthera Phrmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
US9855238B2 (en) 2015-12-18 2018-01-02 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same

Also Published As

Publication number Publication date
US20220347147A1 (en) 2022-11-03
ES2759448T3 (es) 2020-05-11
CA2897343A1 (en) 2014-08-07
EP2762143B1 (en) 2015-12-02
JP2018172409A (ja) 2018-11-08
MX2015009803A (es) 2015-10-29
PH12015501582A1 (en) 2015-10-05
MX2019005082A (es) 2019-08-12
US20150224076A1 (en) 2015-08-13
ZA201505018B (en) 2017-01-25
AU2014211628A1 (en) 2015-07-30
WO2014118097A1 (en) 2014-08-07
JP2016511753A (ja) 2016-04-21
RS54584B1 (en) 2016-08-31
SI2762143T1 (sl) 2016-04-29
HK1200351A1 (zh) 2015-08-07
ZA201605125B (en) 2018-06-27
RU2015136849A (ru) 2017-03-06
GB201301626D0 (en) 2013-03-13
IL265876A (en) 2019-06-30
SG10201806854XA (en) 2018-09-27
JP6363104B2 (ja) 2018-07-25
CN105120872A (zh) 2015-12-02
KR20210088733A (ko) 2021-07-14
KR102274963B1 (ko) 2021-07-08
AU2018206685A1 (en) 2018-08-02
KR20220119524A (ko) 2022-08-29
IL251639A0 (en) 2017-06-29
KR20230047201A (ko) 2023-04-06
CA2897343C (en) 2021-03-16
MX364646B (es) 2019-05-03
NZ709803A (en) 2020-05-29
EP3058943A1 (en) 2016-08-24
PT2762143E (pt) 2016-03-28
HRP20160203T1 (hr) 2016-03-25
KR102434817B1 (ko) 2022-08-19
PL2762143T3 (pl) 2016-06-30
CY1117209T1 (el) 2017-04-05
KR102514913B1 (ko) 2023-03-27
SG11201505457PA (en) 2015-08-28
AU2014211628B2 (en) 2018-04-19
RU2671208C2 (ru) 2018-10-30
CN111214464A (zh) 2020-06-02
SMT201600069B (it) 2016-04-29
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
ES2564025T3 (es) 2016-03-17
US20210244697A1 (en) 2021-08-12
US10813903B2 (en) 2020-10-27
EP3058943B1 (en) 2019-09-25
PH12015501582B1 (en) 2015-10-05
RU2018136872A (ru) 2018-11-27
KR20150112995A (ko) 2015-10-07
CN105120872B (zh) 2020-01-10
US20200069626A1 (en) 2020-03-05
IL239893A (en) 2017-04-30
IL239893A0 (en) 2015-08-31
DK2762143T3 (en) 2016-03-07
EP2762143A1 (en) 2014-08-06
HUE026901T2 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
BR112015018270A2 (pt) composições que compreendem 15-ohepa e métodos de uso das mesmas
CO2018005361A2 (es) Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
MX2017001279A (es) Usos y composiciones de la flagelina.
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112015004515A2 (pt) composição imunogênica
BR112019005329A2 (pt) composições de oligossacarídeos de leite humano purificadas
BR112015023387A2 (pt) composições lipídicas de racecodotril
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
UY35848A (es) Tienopirimidinas
PL423259A1 (pl) Koniugaty przeciwciało-ureaza dla celów terapeutycznych
DOP2016000007A (es) Pirazolpiridinas sustituidas
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
CO2019003761A2 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
CL2018002368A1 (es) Formulaciones de oritavancina
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: AFIMMUNE LIMITED (IE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]